Wake up with Breakfast news in your inbox every market day. Sign Up For Free » Novo Nordisk's weight loss candidate in ...

Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...

Shares of Novo Nordisk surged over 13% in premarket trading Friday, driven by promising topline results from a early-stage trial of amycretin, a new weight-loss drug candidate. If gains hold, this ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Novo Nordisk's U.S.-listed shares are surging 9% Friday morning after the Danish drugmaker reported early stage results for its amycretin weight-loss drug.

Just over a month after its CagriSema readout disappointed analysts, Novo Nordisk released promising data for its obesity drug amycretin. The Danish pharmaceutical giant ended off the week on a high ...

NOW OPEN: 200 Charter Memberships to Benzinga Trade Alerts On Friday, Novo Nordisk A/S NVO released topline results from a phase 1b/2a trial with amycretin intended for once-weekly subcutaneous ...

After Novo Nordisk (NVO) reported that subcutaneous amycretin demonstrated up to 22% absolute weight loss at 36-weeks in a Phase 1/2a trial, BofA thinks this “looks potentially best in class.” The ...

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...

Novo Nordisk's weight loss candidate in question is called amycretin. The company is developing an oral and a subcutaneous version of this medicine. Amycretin is a GLP-1 agonist, but it also ...